Barbara Burtness, MD, of Yale School of Medicine, New Haven, CT, talks about the current survival benefit of early pembrolizumab exposure in recurrent/metastatic head and neck squamous cell carcinoma (HNSCCO and its potential applications in definitive treatment. Its combination with chemo-radiation, along with other immune checkpoint inhibitors are currently being studied. This interview took place at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.